Mode
Text Size
Log in / Sign up
N/A Completed N=172 Treatment

Post Market Safety Study and Effectiveness With Evolence in Subjects With Skin Color Types IV-VI

Non Therapeutic Body Modification
Source: ClinicalTrials.gov NCT00891774 ↗
Enrolled (actual)
172
Serious AEs
1.9%
Results posted
May 2011
Primary outcomePrimary: Safety Endpoint — 155; 0; 3 Participants

Summary

Approximately 165 subjects with Fitzpatrick Skin Color Types IV, V, and VI and a moderate to deep wrinkle between the corner of the nose and the corner of the mouth, will be treated with EVOLENCE® (an approved collagen filler) to smooth and flatten that wrinkle. They will be observed for 6 months to establish safety of the product as it relates to scarring and changes in skin pigment, and long term effectiveness.

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety Endpoint
155; 0; 3 —
SECONDARY
Reduction in Wrinkle Severity Score
— —
SECONDARY
Investigator's Satisfaction of the Overall Treatment
— —
SECONDARY
Subject's Satisfaction of the Overall Treatment
— —

Eligibility Criteria

Inclusion Criteria

  • >18 years of age
  • moderate to deep wrinkle in the Naso-Labial fold
  • Fitzpatrick Skin Type IV, V or VI

Exclusion Criteria

  • Pregnant or nursing females
  • Hx of allergies to related products
  • history of keloids, active skin disease, or previous augmentation of the treatment area
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00891774). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search